GNH USA

Europe — EMA

Mydriasert (Phenylephrine Hydrochloride, Tropicamide)

GNH USA supplies Mydriasert (Phenylephrine Hydrochloride/Tropicamide), a mydriatic agent for pupil dilation during ocular examinations.

Phenylephrine Hydrochloride, Tropicamide

Request sourcing

1
Pack/s

What is Phenylephrine Hydrochloride, Tropicamide?

Phenylephrine Hydrochloride/Tropicamide, the active ingredient in Mydriasert, is a mydriatic agent presented as an ophthalmic solution for ocular use. It induces rapid pupil dilation to facilitate diagnostic eye examinations and fundus evaluation in patients of all ages.

GNH USA supplies Mydriasert as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

What is Phenylephrine Hydrochloride, Tropicamide used for?

Mydriasert, containing phenylephrine hydrochloride and tropicamide, is employed in ophthalmology to achieve pharmacologic mydriasis for diagnostic purposes.

- Diagnostic eye examination: provides rapid pupil dilation to allow thorough retinal and optic nerve assessment. - Fundus photography: facilitates clear imaging of the retina and macula. - Pre‑operative ocular assessment: enables evaluation of intra‑ocular structures before surgery.

What are the side effects of Phenylephrine Hydrochloride, Tropicamide?

Mydriasert may cause a range of ocular and systemic reactions.

Common Side Effects: - Transient ocular discomfort or stinging on instillation. - Blurred vision lasting several hours. - Photophobia due to enlarged pupil. - Mild conjunctival hyperemia. - Temporary increase in intra‑ocular pressure. - Headache.

Serious or Rare Side Effects: - Acute angle‑closure glaucoma. - Severe allergic reaction (e.g., angio‑edema, anaphylaxis). - Systemic hypertension or tachycardia. - Persistent mydriasis. - Corneal edema. - Retinal detachment (very rare).

What precautions apply to Phenylephrine Hydrochloride, Tropicamide?

Before using Mydriasert, consider the following safety measures.

- Assess intra‑ocular pressure: avoid in patients with narrow‑angle glaucoma. - Screen for hypersensitivity: discontinue if allergic signs appear. - Use with caution in cardiovascular disease: phenylephrine may raise blood pressure. - Avoid in pediatric patients unless specifically directed: limited safety data. - Monitor for systemic absorption, especially in patients on monoamine oxidase inhibitors. - Store at below 25°C: keep in the original container, protect from moisture and light.

What does Phenylephrine Hydrochloride, Tropicamide interact with?

Mydriasert can interact with several systemic and ocular agents.

Major Interactions (Avoid): - Monoamine oxidase inhibitors: risk of hypertensive crisis. - Systemic alpha‑adrenergic agonists: additive pressor effects. - Concurrent mydriatics: may cause excessive pupil dilation.

Moderate Interactions (Monitor Closely): - Beta‑blocker eye drops: may reduce intra‑ocular pressure‑lowering effect. - Anticholinergic medications: increased systemic anticholinergic load. - Topical corticosteroids: potential for heightened intra‑ocular pressure when combined.

Frequently asked questions

What is Mydriasert used for?+
Mydriasert is an ophthalmic preparation containing phenylephrine hydrochloride and tropicamide. It is used to produce rapid pupil dilation (mydriasis) during diagnostic eye examinations, fundus photography, and pre‑operative ocular assessments, allowing clinicians to view the retina and other intra‑ocular structures clearly.
How does phenylephrine hydrochloride work in Mydriasert?+
Phenylephrine hydrochloride is an alpha‑1 adrenergic receptor agonist. By stimulating these receptors on the radial iris dilator muscle, it causes the muscle to contract, pulling the iris outward and contributing to pupil enlargement when combined with tropicamide.
What is the usual dose of Mydriasert?+
The appropriate dose of Mydriasert is determined by the prescribing eye care professional based on the specific examination needs and patient characteristics. The prescriber will select the number of drops and timing required for adequate mydriasis.
Is Mydriasert safe during pregnancy or breastfeeding?+
Safety data for Mydriasert in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any potential risk to the fetus or infant, and the decision should be made by the treating physician after evaluating the individual situation.
How do I order Mydriasert from GNH USA?+
To order Mydriasert, submit an enquiry on the product page at gnh-usa.com, specifying the required quantity. GNH USA supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.
How does Mydriasert compare with other mydriatic agents?+
Mydriasert combines an alpha‑1 agonist (phenylephrine) with a muscarinic antagonist (tropicamide), offering rapid and sustained dilation. Compared with single‑agent drops such as tropicamide alone, the combination often achieves quicker onset and greater pupil size, which can be advantageous for time‑sensitive examinations.
What are the storage and handling requirements for Mydriasert?+
Mydriasert should be stored at temperatures below 25 °C, in its original packaging, protected from moisture and direct light. Keep the container tightly closed when not in use and discard any solution that appears discolored or contaminated.
How is Mydriasert administered?+
Mydriasert is applied topically to the eye as an ophthalmic solution. The prescriber will instruct the patient on the number of drops per eye and the interval between applications, typically instilling the drops directly onto the conjunctival sac.
What are the most serious risks associated with Mydriasert?+
The most serious risks include acute angle‑closure glaucoma, severe allergic reactions such as anaphylaxis, and systemic hypertension. Patients should be monitored for signs of these conditions, and the medication should be discontinued immediately if they occur.
Who should not use Mydriasert?+
Mydriasert should not be used in patients with known hypersensitivity to phenylephrine, tropicamide, or any excipients, nor in individuals with narrow‑angle or uncontrolled glaucoma, severe cardiovascular disease, or those taking monoamine oxidase inhibitors without medical supervision.
Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.
Send a sourcing enquiry for this product →

Product details

Drug
Phenylephrine Hydrochloride, Tropicamide
Route
Ocular Use
Manufacturer
Laboratoires Thea
Origin
EU

Related products

Mydriasert

Mydriasert

Phenylephrine Hydrochloride, Tropicamide

Laboratoires Thea
EU
Mydriasert

Mydriasert

Phenylephrine Hydrochloride, Tropicamide

Laboratoires Thea
EU
Mydriasert

Mydriasert

Phenylephrine Hydrochloride, Tropicamide

Laboratoires Thea
EU
Mydriasert

Mydriasert

Phenylephrine Hydrochloride, Tropicamide

Laboratoires Thea
EU